Efficacy and safety of long-term (>7 year) alemtuzumab therapy for refractory T-cell large granular lymphocytic leukaemia.
Olteanu
Horatiu
H
Harrington
Alexandra M
AM
Ramirez
Sarah
S
Kroft
Steven H
SH
Hari
Parameswaran
P
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D054066:Leukemia, Large Granular Lymphocytic / Q000188:drug therapy*; D008875:Middle Aged; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000139:chemically induced
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab